Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1447-9. doi: 10.1158/1055-9965.EPI-14-0520.

Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial.

Author information

1
Departments of Cancer Biology, Urology, and Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina gschwart@wakehealth.edu.

Abstract

The effects of blood levels of 25-hydroxyvitamin D (25-OHD) on the risk of total, low-, and high-grade prostate cancer were examined in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and the Prostate Cancer Prevention Trial (PCPT). In the SELECT study, plasma 25-OHD levels were associated with a linear decrease in prostate cancer risk for high-grade cancers in African American men and an apparent "U"-shaped effect in other men. The "U-shaped" curve may reflect detection bias. In the PCPT study, in which detection bias was minimized, serum 25-OHD levels were associated with a linear decrease in the risk of high-grade prostate cancers. The results from these large prevention trials support the hypothesis that circulating levels of 25-OHD decrease the risk of clinically relevant prostate cancers.

PMID:
25085835
DOI:
10.1158/1055-9965.EPI-14-0520
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center